Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Progression‐free survival · people with advanced gastric cancer

Oxaliplatin showed no clear difference in progression‐free survival compared with the same regimen including cisplatin (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.88 [0.66, 1.19]
4 studies · 1034 participants
Low

Progression‐free survival · people with metastatic CRC

Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.6 [0.55, 0.66]
1 study · 627 participants
Moderate